About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Oncolys BioPharma Inc.(4588) Summary

4588
TSE Growth
Oncolys BioPharma Inc.
515
JPY
+33
(+6.85%)
Apr 10, 2:00 pm JST
3.51
USD
Apr 10, 1:00 am EDT
Result
PTS
outside of trading hours
515
Apr 10, 1:59 pm JST
Summary Chart Historical News Financial Result
PER
PBR
4.67
Yield
ー%
Margin Trading Ratio
1,106.35
Stock Price
Apr 10, 2025
Opening Apr 10, 9:12 am
519 JPY 3.52 USD
Previous Close Apr 9
482 JPY 3.31 USD
High Apr 10, 11:11 am
520 JPY 3.54 USD
Low Apr 10, 9:25 am
507 JPY 3.44 USD
Volume
486,000
Trading Value
0.25B JPY 1.70M USD
VWAP
514.34 JPY 3.51 USD
Minimum Trading Value
51,500 JPY 351 USD
Market Cap
0.01T JPY 0.09B USD
Number of Trades
813
Liquidity & Number of Trades
As of Apr 10, 2025
Liquidity
High
1-Year Average
1,229
1-Year High Nov 12, 2024
10,905
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 4, 2025 0 3,836,100
Mar 28, 2025 800 4,641,000 5801.25
Mar 21, 2025 500 4,424,300 8848.60
Mar 14, 2025 0 4,531,000
Mar 7, 2025 0 4,578,700
Company Profile
Oncolys BioPharma Inc. is a drug discovery venture focusing on rare cancers and severe infectious diseases, utilizing proprietary virus technology.
Sector
Pharmaceuticals
Oncolys BioPharma Inc. promotes the development of cancer virus therapy and severe infectious disease treatments using its proprietary virus genetic modification technology. Its main pipeline includes Telomelysin, which specifically proliferates in cancer cells, and OBP-702, a next-generation Telomelysin with even more potent anti-cancer activity. Additionally, OBP-601, which has been developed as an HIV infection treatment, is now being repurposed as a treatment for neurodegenerative diseases. The company is also developing OBP-2011 as a viral infection treatment. Oncolys BioPharma Inc. is also working on TelomeScan, a cancer diagnostic agent for ultra-early detection or prognosis testing of cancer. The company employs a fabless management strategy to optimize development efficiency and expenses.